CL2024001399A1 - Tratamiento de trastornos hepáticos con un agonista del thr-beta - Google Patents

Tratamiento de trastornos hepáticos con un agonista del thr-beta

Info

Publication number
CL2024001399A1
CL2024001399A1 CL2024001399A CL2024001399A CL2024001399A1 CL 2024001399 A1 CL2024001399 A1 CL 2024001399A1 CL 2024001399 A CL2024001399 A CL 2024001399A CL 2024001399 A CL2024001399 A CL 2024001399A CL 2024001399 A1 CL2024001399 A1 CL 2024001399A1
Authority
CL
Chile
Prior art keywords
thr
treatment
liver disorders
beta agonist
agonist
Prior art date
Application number
CL2024001399A
Other languages
English (en)
Spanish (es)
Inventor
T Jones Christopher
K Quirk Erin
Guo Sheng
Duan Matt
Bian Jianwei
KLUCHER Kevin
Barry Crittenden D
Jin Feng
Dong Qianqian
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of CL2024001399A1 publication Critical patent/CL2024001399A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
CL2024001399A 2021-11-11 2024-05-09 Tratamiento de trastornos hepáticos con un agonista del thr-beta CL2024001399A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021130083 2021-11-11
CN2022097426 2022-06-07

Publications (1)

Publication Number Publication Date
CL2024001399A1 true CL2024001399A1 (es) 2024-11-08

Family

ID=86335128

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001399A CL2024001399A1 (es) 2021-11-11 2024-05-09 Tratamiento de trastornos hepáticos con un agonista del thr-beta

Country Status (14)

Country Link
US (1) US20240293416A1 (https=)
EP (1) EP4429666A4 (https=)
JP (1) JP2024544538A (https=)
KR (1) KR20240101642A (https=)
CN (1) CN118871113A (https=)
AU (1) AU2022388507A1 (https=)
CA (1) CA3238108A1 (https=)
CL (1) CL2024001399A1 (https=)
CO (1) CO2024007225A2 (https=)
IL (1) IL312637A (https=)
MX (1) MX2024005647A (https=)
PE (1) PE20241327A1 (https=)
TW (1) TW202332447A (https=)
WO (1) WO2023083288A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
WO2021050945A1 (en) 2019-09-12 2021-03-18 Terns, Inc. Thyroid hormone receptor beta agonist compounds
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2025245216A1 (en) * 2024-05-22 2025-11-27 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-beta agonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018075650A1 (en) * 2016-10-18 2018-04-26 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a thr-beta agonist
AR115666A1 (es) * 2018-07-02 2021-02-10 Madrigal Pharmaceuticals Inc Formas sólidas de 2-(3,5-dicloro-4-((5-isopropil-6-oxo-1,6-dihidropiridazin-3-il)oxi)fenil)-3,5-dioxo-2,3,4,5-tetrahidro-1,2,4-triazin-6-carbonitrilo
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
WO2020228577A1 (zh) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 一种哒嗪酮衍生物及其应用
TW202128668A (zh) * 2019-12-16 2021-08-01 大陸商江蘇恆瑞醫藥股份有限公司 并環類衍生物、其製備方法及其在醫藥上的應用
US20210379043A1 (en) * 2020-05-13 2021-12-09 Terns Pharmaceuticals, Inc. Combination treatment of liver disorders
CN114437034A (zh) * 2020-11-06 2022-05-06 深圳微芯生物科技股份有限公司 一种酞嗪类化合物的可药用盐、晶型及其制备方法

Also Published As

Publication number Publication date
TW202332447A (zh) 2023-08-16
WO2023083288A1 (en) 2023-05-19
KR20240101642A (ko) 2024-07-02
CN118871113A (zh) 2024-10-29
EP4429666A1 (en) 2024-09-18
CA3238108A1 (en) 2023-05-19
US20240293416A1 (en) 2024-09-05
CO2024007225A2 (es) 2024-10-31
AU2022388507A1 (en) 2024-06-20
EP4429666A4 (en) 2025-12-24
JP2024544538A (ja) 2024-12-03
IL312637A (en) 2024-07-01
PE20241327A1 (es) 2024-06-26
MX2024005647A (es) 2024-05-24

Similar Documents

Publication Publication Date Title
CL2024001399A1 (es) Tratamiento de trastornos hepáticos con un agonista del thr-beta
BR112021022363A2 (pt) Composições e métodos para fabricação de células t
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CL2020000907A1 (es) Terapias de combinación y usos de las mismas.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
BR112022023048A2 (pt) Tratamento de combinação de distúrbios hepáticos
PE20180260A1 (es) Metodos y kits para tratar la depresion
CR11485A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
NI201700035A (es) Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr
UY38721A (es) INHIBIDORES DE MOLÉCULAS PEQUEÑAS DE QUINASA INDUCTORA DE NF-kB
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
PE20211961A1 (es) Terapia de combinacion de radioinmunoconjugados con inhibidores de danos y reparaciones del adn
MX2023011853A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer.
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
CL2021001363A1 (es) Métodos de tratamiento de enfermedades con inhibidores de magl.
BR112022022952A2 (pt) Tratamento combinado de distúrbios hepáticos
BR112018000786A2 (pt) métodos e composições usando bifidobacterium longum para modular a reatividade emocional e tratar ou evitar perturbações subclínicas do estado de humor
BR112023020669A2 (pt) Terapias de combinação para o tratamento de câncer
MX2019004402A (es) Metodos para el tratamiento de las condiciones relacionadas con la inflamacion utilizando moduladores antiinflamatorios y metabolicos pluripotentes.
MX2021002761A (es) Metodos para tratar la pancreatitis.
MX2022011845A (es) Terapia combinada con un inhibidor de idh mutante y un inhibidor de bcl-2.
MX2021006915A (es) Inhibidores de cxcr7 para el tratamiento de cancer.
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
BR112019008241A2 (pt) tratamento do prurigo nodular